Mark Iwicki

Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Prior to joining Civitas, he was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Sumitomo Dainippon Pharmaceuticals. Mark also previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently also sits on the board of directors for Kala Pharmaceuticals, Allergen Research Corporation and Taris Biomedical.